BAI Announces 2018 Outstanding Achievement and People’s Choice Awards Winners
11.10.2018 19:31:00 EEST | Business Wire | Press release
Today, BAI announced the 2018 Global Innovation Awards Outstanding Achievement and People’s Choice Award winners. Winners of these special categories were announced live during BAI Beacon in Orlando, Fla.
The BAI Global Innovation Awards recognize industry leaders and showcase what leading financial services innovators in all regions of the world are doing to deliver new value to customers and employees as well as improve efficiencies and profitability for their organizations.
BAI’s Outstanding Achievement Awards consist of three special categories that honor and recognize financial services organizations that have made exceptional strides in driving positive change in the industry. All BAI Global Innovation Award nominees are considered for the honor.
The 2018 Outstanding Achievement Award winners are:
Disruptive Innovation in Financial Services
NovoPayment – Embedding FinServ in Gig Value Chain
Outstanding Use of AI in Financial Services
Ping An Technology – Emotion Recognition Based Financial Risk Management System
Most Innovative Finserv of the Year
USAA
In addition to BAI’s Outstanding Achievement Awards, the People’s Choice Award winner was also announced at BAI Beacon. Contenders for this new category are comprised of finalists from customer-facing Global Innovation Awards categories. Voters had the opportunity to recognize the innovation in which they feel is most impactful for the industry.
The 2018 People’s Choice Award winner is Bank of America – Meet Erica: Bank of America’s New Virtual Financial Assistant.
Congratulations to all of the 2018 Global Innovation Award winners. To see the full list of BAI Global Innovation Award winners and to learn more, please visit BAIGlobalInnovations.com.
About BAI
As a nonprofit, independent organization, BAI delivers the financial services industry’s most actionable insights, enabling leaders to make smart business decisions every day. BAI is passionate about the trusted information and powerful tools that provide leaders with the clarity and confidence needed to drive positive change and move the financial services industry forward. For more information, visit www.bai.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005586/en/
Contact information
William Mills Agency, Atlanta
Joelle Chiasson, 678-781-3074
joelle@williammills.com
or
BAI,
Chicago
Jennifer Divelbiss, 312-683-2346
jdivelbiss@bai.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom